Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Guggenheim raised its price target on UroGen Pharma (NASDAQ:URGN) to $32.00 from $30.00 on Friday, while maintaining a Buy rating following the company’s second-quarter earnings report. According to InvestingPro data, analyst targets for URGN currently range from $16 to $50, with the stock trading near $18.59. The company appears undervalued based on InvestingPro’s Fair Value analysis.
The research firm highlighted UroGen’s focus on executing the launch of Zusduri, which received approval in June for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The company views this as a potential $5 billion U.S. market where Zusduri could achieve over $1 billion in peak sales. The company’s impressive gross profit margin of nearly 90% and strong recent performance, with a 73% gain over the past six months, suggest potential for significant growth. InvestingPro subscribers have access to 10+ additional insights about URGN’s financial health and growth prospects.
UroGen began a phased launch with product availability starting July 1 using a miscellaneous J-code, with management expecting an inflection point in the first quarter of 2026 after receiving a permanent J-code. The company reported progress in sales force expansion, treatment site activation, and provider outreach.
For the second quarter, UroGen’s Jelmyto sales reached $24.2 million, exceeding consensus estimates of $23.1 million by 5%. The company has not yet seen paid claims for Zusduri. UroGen’s total revenue for the last twelve months stands at $91.9 million, with a year-over-year growth rate of 9%. For deeper insights into UroGen’s financial performance and growth potential, access the comprehensive Pro Research Report available exclusively on InvestingPro.
Guggenheim updated its model to include projected Zusduri sales of $21 million in 2025, $125 million in 2026, and $280 million in 2027. The firm also noted that UroGen’s Phase III UTOPIA (EGX:UTOP) trial of UGN-103 has completed enrollment, with top-line results expected by year-end 2025.
In other recent news, UroGen Pharma Ltd reported its second-quarter 2025 earnings, with a net loss of $1.50 per share, which was greater than the anticipated loss of $0.83 per share. The company, however, posted net product revenues of $24.2 million, surpassing the forecasted $23.13 million, marking an 11% increase year-over-year. Despite exceeding revenue expectations, the larger-than-expected earnings per share loss has been a point of concern among investors. The revenue growth indicates a positive trend, although the earnings per share figure suggests challenges remain. These developments are part of UroGen Pharma’s recent financial disclosures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.